To support its vision of beating cancer in the United Kingdom, Cancer Research U.K., , a not-for-profit cancer research organization, will work with Oracle Health Sciences Translational Research Center as the foundation for a new analytical environment to help the charity combine the genetic and clinical data from its Stratified Medicine Program.
Together with AstraZeneca, Pfizer and the U.K. government's Technology Strategy Board, Cancer Research U.K. is working to demonstrate a national service that will provide standardized, high-quality and cost-effective genetic testing of tumors linked to clinical data. This system has already tested 2,000 tumors from patients across 24 clinical sites and set up data capture covering diagnostics, genetics, treatment and outcomes.
Cancer Research U.K. will use Cohort Explorer, part of the Oracle Health Sciences Translational Research Center, to create a flexible, web-accessible analytical platform and interface that enables program affiliates to effectively and rapidly search and retrieve anonymized diagnostic, treatment and outcome data to accelerate research.
The platform will enable researchers and physicians to gain the insight needed to identify patient populations with similar characteristics and advance personalized cancer treatments.
The new analytical platform “is an exciting addition to the future of our Stratified Medicine Program and its goal of combining genetic testing of tumors with clinical data capture to determine more effective treatment,” said Monica Jones, enterprise architect and informatics lead of Cancer Research U.K.’s Stratified Medicine Program.
“Organizations committed to advancing medical science require powerful analytical solutions to reveal insight that was previously locked away at the molecular level,” said Neil de Crescenzo, senior vice president and general manager of Oracle Health Sciences.
Cancer Research U.K. is a leading cancer charity dedicated to saving lives through research. Its groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives, and is funded entirely by the public. It supports the research of more than 4,000 scientists, doctors and nurses.